文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

玻连蛋白驱动淀粉样沉积通过整合素通路破坏线粒体稳态的人源化ATTR心肌病小鼠模型

Vitronectin-driven amyloid deposition disrupts mitochondrial homeostasis via integrin-mediated pathway in a humanized mouse model of transthyretin cardiac amyloidosis.
PubMed 文献 · Eur Heart J · 2026-08-11

本研究建立表达野生型或V142I突变型转甲状腺素蛋白的人源化敲入小鼠,二者均出现年龄依赖性心脏淀粉样变性、舒张功能障碍和生存率降低,V142I株更显著。玻连蛋白与TTR纤维共定位并促进纤维聚集,其敲低可减少淀粉样负荷并保护心功能;TTR淀粉样物抑制整合素αvβ3/FAK/Akt信号导致线粒体动力学失衡,低剂量西仑吉肽恢复该信号可改善线粒体功能和舒张功能障碍。

要点

  • 人源化hTTRWT和hTTRV142I小鼠可复现年龄依赖性心脏淀粉样变性和舒张功能障碍。
  • 玻连蛋白与TTR纤维共定位并促进纤维聚集,敲低玻连蛋白减少淀粉样负荷并保护心功能。
  • 调节整合素αvβ3信号可能成为ATTR-CM超越TTR抑制的补充治疗策略。

核心结论

  • 玻连蛋白主动驱动心脏淀粉样沉积,整合素αvβ3/FAK/Akt信号破坏将淀粉样-ECM相互作用与线粒体功能障碍联系起来。
  • 调节整合素信号代表ATTR-CM超越TTR抑制的潜在补充治疗策略。

研究设计与样本

  • 研究建立表达野生型(hTTRWT)或V142I突变型(hTTRV142I)转甲状腺素蛋白的人源化敲入小鼠模型。
  • 通过刚果红染色、电镜、超声心动图和心脏磁共振评估淀粉样负荷、心脏结构和功能。
  • 采用基因沉默和低剂量西仑吉肽药理干预研究玻连蛋白和整合素信号的功能作用。

主要发现

  • hTTRWT和hTTRV142I小鼠均出现年龄依赖性心脏淀粉样变性、舒张功能障碍和生存率降低,hTTRV142I株更显著。
  • 玻连蛋白与TTR纤维共定位,促进纤维聚集;敲低玻连蛋白减少淀粉样负荷并保护心脏功能。
  • TTR淀粉样物抑制整合素αvβ3/FAK/Akt信号,导致线粒体过度分裂、线粒体自噬增强和氧化磷酸化受损。
  • 低剂量西仑吉肽恢复αvβ3信号,使线粒体动力学正常化、改善生物能量学并改善舒张功能障碍,尽管淀粉样应激持续存在。

临床怎么用

  • 人源化hTTRWT和hTTRV142I小鼠可作为研究ATTR-CM细胞生物学机制的可重复动物模型。
  • 靶向玻连蛋白或整合素αvβ3/FAK/Akt信号可能成为ATTR-CM的补充治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive cause of heart failure, especially in the ageing society, but cellular biological mechanism studies are limited by the lack of robust animal models. Vitronectin (VTN), an extracellular matrix (ECM) glycoprotein enriched in amyloid deposits, may contribute to amyloidogenesis, yet its pathogenic role in ATTR-CM remains undefined. METHODS: Humanized knock-in mice expressing either wild-type (hTTRWT) or V142I mutant transthyretin (hTTRV142I) were generated. Amyloid burden, cardiac structure, and function were assessed by Congo red staining, electron microscopy, echocardiography, and cardiac magnetic resonance. The functional role of VTN and integrin signalling was studied using genetic silencing and pharmacological intervention with low-dose cilengitide. RESULTS: Both hTTRWT and hTTRV142I mice developed age-dependent cardiac amyloidosis with diastolic dysfunction and reduced survival, especially in the hTTRV142I strain. VTN co-localized with TTR fibrils, promoted fibril aggregation, reduced amyloid burden upon its knockdown, and preserved cardiac function. Mechanistically, TTR amyloid suppressed integrin αvβ3/FAK/Akt signalling, leading to marked mitochondrial dysregulation characterized by excessive fission, enhanced mitophagy, and impaired oxidative phosphorylation. Restoration of αvβ3 signalling with cilengitide normalized mitochondrial dynamics, improved bioenergetics, and ameliorated diastolic dysfunction despite persistent amyloid stress. CONCLUSIONS: Two reproducible ATTR-CM models that recapitulate the steadily progressive course of human disease were established. Furthermore, VTN actively drives cardiac amyloid deposition, and disruption of integrin αvβ3/FAK/Akt signalling links amyloid-ECM interactions to mitochondrial dysfunction. Therefore, modulation of integrin signalling represents a potential complementary therapeutic strategy in ATTR-CM beyond TTR suppression.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Qiu Z, Fan Y, Qin J, et al. Vitronectin-driven amyloid deposition disrupts mitochondrial homeostasis via integrin-mediated pathway in a humanized mouse model of transthyretin cardiac amyloidosis. Eur Heart J. 2026. PMID: 42578966. doi:10.1093/eurheartj/ehag598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。